All In MedTech

FDA Clearance Tracker · P010062-S014

Boston Orthokeratology (oprifocon A) Shaping lens for Overnight Wear for Bausch + Lomb Vision Shaping Treatment

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 20, 2025

Approved

Time to decision

90 days

Received Nov 22, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P010062-S014
Device name
Boston Orthokeratology (oprifocon A) Shaping lens for Overnight Wear for Bausch + Lomb Vision Shaping Treatment
Applicant
Bausch & Lomb
Applicant location
Rochester, NY
Received
Nov 22, 2024
Decided
Feb 20, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P010062

Device type

Device class
Class III
Regulation
21 CFR 886.5916
Specialty
Ophthalmology

Every decision under product code NUU

FDA's approval statement

As written in FDA's record.

implementing a design module of the existing software for generating lathe cutting files to provide alternative posterior lens designs for Boston Orthokeratology (oprifocon A) Shaping Lens for Overnight Wear for Bausch + Lomb Vision Shaping Treatment

Source documents

Other decisions for Bausch & Lomb

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.